MAP2K7 and non-small cell lung carcinoma: The introduction of combined BRAF and MEK inhibition (e.g., dabrafenib plus trametinib; encorafenib plus binimetinib) has significantly advanced treatment for BRAF V600E-mutant NSCLC (22).